Research Analysts Set Expectations for CRVS Q4 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Research analysts at HC Wainwright issued their Q4 2024 EPS estimates for Corvus Pharmaceuticals in a report released on Thursday, January 2nd. HC Wainwright analyst S. Lee expects that the company will post earnings per share of ($0.12) for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2029 earnings at $0.49 EPS.

Several other equities analysts have also commented on CRVS. StockNews.com lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. Oppenheimer increased their price objective on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. LADENBURG THALM/SH SH raised their target price on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Finally, Mizuho raised Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Trading Up 7.4 %

Shares of CRVS opened at $5.83 on Friday. The firm has a market capitalization of $374.62 million, a price-to-earnings ratio of -6.27 and a beta of 1.07. The firm’s fifty day simple moving average is $7.67 and its 200-day simple moving average is $5.29. Corvus Pharmaceuticals has a twelve month low of $1.30 and a twelve month high of $10.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Samlyn Capital LLC raised its holdings in shares of Corvus Pharmaceuticals by 160.7% in the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after buying an additional 3,774,658 shares during the last quarter. Marshall Wace LLP purchased a new stake in Corvus Pharmaceuticals during the 2nd quarter valued at approximately $136,000. Cubist Systematic Strategies LLC acquired a new stake in Corvus Pharmaceuticals during the 2nd quarter worth approximately $44,000. Point72 Asset Management L.P. purchased a new position in shares of Corvus Pharmaceuticals in the 2nd quarter valued at approximately $10,855,000. Finally, Avity Investment Management Inc. increased its holdings in shares of Corvus Pharmaceuticals by 138.2% in the third quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock valued at $146,000 after purchasing an additional 16,000 shares during the period. Hedge funds and other institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.